

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *RSC Chem. Biol.*, 2023,
4, 587Siderocalin fusion proteins enable a new $^{86}\text{Y}/^{90}\text{Y}$ theranostic approach†Alexia G. Cosby,^a Trevor Arino,^{ab} Tyler A. Bailey,^{ab} Matthew Buerger,^c
Joshua J. Woods,^a Luis M. Aguirre Quintana,^a Jennifer V. Alvarenga Vasquez,^a
Jennifer N. Wacker,^a Alyssa N. Gaiser,^a Roland K. Strong^c and
Rebecca J. Abergel^{id} *^{ab}

The mammalian protein siderocalin binds bacterial siderophores and their iron complexes through cation- π and electrostatic interactions, but also displays high affinity for hydroxypyridinone complexes of trivalent lanthanides and actinides. In order to circumvent synthetic challenges, the use of siderocalin-antibody fusion proteins is explored herein as an alternative targeting approach for precision delivery of trivalent radiometals. We demonstrate the viability of this approach *in vivo*, using the theranostic pair ^{90}Y (β^- , $t_{1/2} = 64$ h)/ ^{86}Y (β^+ , $t_{1/2} = 14.7$ h) in a SKOV-3 xenograft mouse model. Ligand radiolabeling with octadentate hydroxypyridinone 3,4,3-LI(1,2-HOPO) and subsequent protein binding were achieved at room temperature. The results reported here suggest that the rapid non-covalent binding interaction between siderocalin fusion proteins and the negatively charged Y(III)-3,4,3-LI(1,2-HOPO) complexes could enable purification-free, cold-kit labeling strategies for the application of therapeutically relevant radiometals in the clinic.

Received 5th April 2023,
Accepted 2nd June 2023

DOI: 10.1039/d3cb00050h

rsc.li/rsc-chembio

The rational chemical design of radiometal-based theranostics relies on (1) pairing the radiological half-life of the radiometal with the biological half-life of the targeting vector; (2) highly kinetically and thermodynamically stable radiometal chelation through rational ligand design; and (3) facile radiolabeling conditions that are amenable to biological targeting vectors, which are often temperature-sensitive.

In this context, the yttrium isotopes ^{90}Y and ^{86}Y make an ideal theranostic pair. Yttrium-90 (β^- , $\beta_{\text{ave}} = 0.934$ MeV, $t_{1/2} = 64$ hr) is a pure β^- emitter with a multi-day half-life that is highly suitable for use with antibody targeting vectors, which have longer biological half-lives compared to antibody fragments or peptides. The therapeutic potential of this isotope has been highlighted by the clinical approval of Zevalin, ^{90}Y -ibritumomab-tiuxetan, in 2002, for the treatment of non-Hodgkin lymphoma. This success has prompted further investigation into antibody conjugates incorporating ^{90}Y .¹

Given the clinical success of ^{90}Y -based radiopharmaceuticals, it is advantageous to find a chemically equivalent diagnostic radioisotope to image biodistribution and pharmacokinetics *in vivo*. Yttrium is often treated as a pseudo-lanthanide, owing to its preference to exist in the trivalent oxidation state and comparable ionic radius to those of the lanthanides.² Previous studies have investigated the use of ^{111}In , ^{177}Lu or other substitute diagnostic PET or SPECT isotopes for ^{90}Y .³ However, these isotopes can display different coordination chemistry preferences, resulting in release of the metal from the chelator or transchelation by endogenous species *in vivo*.

The positron-emitter, ^{86}Y (β^+ , $\beta_{\text{ave}} = 0.660$ MeV, $t_{1/2} = 14.7$ h), is an ideal diagnostic partner for ^{90}Y , given its chemical equivalence, relieving concern for off-target uptake or *in vivo* instability. Previous $^{86}/^{90}\text{Y}$ chelation approaches have focused on the non-linear scaffold diethylenetriamine pentaacetate (DTPA)^{4,5} and its derivatives, which allow for rapid complexation kinetics without requiring heat, but at the cost of long-term thermodynamic stability *in vivo* and leading to increased off-target uptake in healthy tissues. Macrocyclic 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) has also been used to chelate $^{86}/^{90}\text{Y}$, but radiolabeling requires elevated temperatures (> 90 °C), which are incompatible with heat-sensitive proteins, including antibodies. Efficient use of DOTA thus entails additional processes for targeting vector conjugation as well as subsequent purification steps, in contrast to desired single, cold-kit radiolabeling assembly

^a Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA. E-mail: abergel@berkeley.edu^b Department of Nuclear Engineering, University of California, Berkeley, CA 94720, USA^c Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA† Electronic supplementary information (ESI) available: Experimental, fluorescence quenching, radiolabeling, and PET imaging data. See DOI: <https://doi.org/10.1039/d3cb00050h>

approaches. The octadentate hydroxypyridinonate chelator 3,4,3-LI(1,2-HOPO), or HOPO, is composed of a spermine backbone and four 1-hydroxypyridin-2-one binding units, and has demonstrated high binding affinity for trivalent (Y(III)-HOPO, $\log \beta_{110} = 20.76$) and tetravalent (Pu(IV)-HOPO, $\log \beta_{110} = 43.1 \pm 0.05$; Th(IV)-HOPO, $\log \beta_{110} = 40.1$) metal ions, including transition, rare earth, and actinide elements.⁶

While ligands such as HOPO may form highly stable complexes *in vivo*, another requirement for a successful theranostic agent is the incorporation of a targeting vector, which must display a biological half-life compatible with the radiological half-life of the nuclide, and should be synthetically accessible. Antibodies are well-established targeting vectors for cancer therapy. However, despite their clinical utility and ongoing primacy in preclinical theranostic literature, the synthesis of ligands that enable facile chemical conjugation to antibodies often poses a large synthetic challenge. A bifunctional derivative of HOPO incorporating a para-benzyl-isothiocyanate pendant arm was previously synthesized and conjugated to trastuzumab for use with ⁸⁹Zr for PET imaging.¹⁴ Although this conjugate showed promising *in vivo* stability and significant uptake in tumors, the broader implementation of this construct for therapeutic purposes is likely hampered by its challenging chemical synthesis, which requires 13 steps.

Another conjugation approach is to construct fusion proteins where tyrosine or histidine residues of the antibody or antibody fragment are radioiodinated, such as a ¹²⁵I-labeled albumin fusion protein construct that showed enhanced uptake in colon carcinoma xenografts.¹⁵ Most fusion protein systems utilize radioiodination of protein tyrosine residues, however these often require harsh chemical reductants and some systems are prone to deiodination *in vivo*.¹⁶ Additionally, non-specific tyrosyl iodination can also affect antigen binding.

A simpler approach would be to design a fusion protein system that could allow for rapid, room temperature labeling. The mammalian protein siderocalin (Scn) is known to bind bacterial siderophore complexes such as ferric enterobactin (Fe(III)-Ent) through noncovalent, electrostatic interactions (K_d [Fe(III)-Ent] = 0.4 nM, Table 1), and has also shown selective affinity for HOPO complexes of trivalent lanthanides and actinides, which are negatively charged, in contrast to

corresponding neutral complexes of tetravalent actinides (Table 1).^{6,8,11} Previously, we have capitalized on the high affinity and stability of this interaction to crystallize M(III)-HOPO complexes within the Scn protein, to further confirm the geometric tolerance of the calyx.^{6,11} We hypothesized we could take further advantage of the high affinity interaction between Scn and HOPO complexes to design a radiotheranostic system, where only trivalent radiometals with chemically equivalent theranostic isotopes such as ^{86/90}Y or ^{44/47}Sc are recognized.

A novel approach to circumvent synthetic challenges and exhaustive post-labeling or post-conjugation processes is described herein, through the development of a fusion protein system, where the Scn protein is fused with the HER2+ targeting antibody trastuzumab (IgG-Scn) or a small antibody fragment (Fab-Scn) (Fig. 1). As a theranostic pair, we employ the PET diagnostic isotope ⁸⁶Y and the therapeutic isotope ⁹⁰Y for visualization and therapeutic effect in a SKOV-3 xenograft mouse model. Our approach provides the first validation of a theranostic fusion protein system with cold-kit labeling potentially adaptable to a variety of ligand, protein, and radiometal systems.

Results and discussion

We first validated the binding of the HOPO complexes of rare earth Y(III) and Sc(III) within the Scn calyx. Adapting a previously developed method, the dissociation constant or K_d was determined by monitoring the fluorescence quenching of tryptophan ($\lambda_{\text{ex/em}} = 281/380$ nm) residues within the protein binding pocket, which is quenched upon recognition of the M-HOPO complex. The results indicate that Y(III)-HOPO and Sc(III)-HOPO both bind rapidly within Scn, with dissociation constants of 2.4 and 5.5 nM respectively (Table 1 and Fig. S2, S3, ESI†). These binding constants are lower than other larger trivalent lanthanides such as Eu(III) or Gd(III) ($K_d = 14$ or 18 nM), potentially indicating a relationship between metal ionic radius and the strength of the noncovalent bonding interactions within the pocket, although studies investigating those trends are on-going. Of note, the decay product of ⁹⁰Y, ⁹⁰Zr, is not recognized by the protein, owing to +4 oxidation state of Zr and the overall neutral charge of the corresponding HOPO complex, as indicated by the lack of Scn binding to Zr(IV)-HOPO (Table 1).

Fusion proteins IgG-Scn and Fab-Scn were recombinantly expressed as reported previously, with Scn moieties fused to the antibody heavy chain C-termini.^{17,18}

The final ^{86/90}Y-HOPO protein constructs (protein = Scn, Fab-Scn, or IgG-Scn) were assembled in two steps. In short, HOPO was dissolved in DMSO and ⁹⁰YCl₃ or ⁸⁶YCl₃ was added at a 1:100 (M:HOPO) molar ratio, followed by incubation at room temperature for 5 minutes. Solutions were further diluted with 1X DPBS and a pH of 7.4 was confirmed by spotting onto pH paper. Subsequently, the ⁸⁶Y-HOPO or ⁹⁰Y-HOPO solution was added to 200 equivalents of wildtype Scn, Fab-Scn, or IgG-Scn fusion proteins in a PBS matrix and then incubated at room temperature for an additional 5 minutes.

Table 1 Summary of M(III/IV)-HOPO stability constants ($\log \beta_{110}$) and Siderocalin (Scn) dissociation constants (K_d). Superscript denotes reference number

M-HOPO	$\log \beta_{110}$ (stdev)	Scn-M-HOPO K_d [nM (stdev)]
Fe(III)-Ent	49 ⁷	0.4 ⁸
Y(III)-HOPO	20.76(0.09) ⁹	2.4 (0.6) This Work
Sc(III)-HOPO	25.16(0.09) ⁹	5.5(1.1) This Work
Zr(IV)-HOPO	43.1 ⁶	No binding
Sm(III)-HOPO	19.7 ¹⁰	13(3) ¹¹
Eu(III)-HOPO	20.2 ¹⁰	14(1) ¹¹
Gd(III)-HOPO	20.5(1) ¹⁰	18(2) ¹¹
Th(IV)-HOPO	40.1 ¹²	No binding
Pu(IV)-HOPO	43.5 ¹²	110(21) ¹¹
Am(III)-HOPO	20.4(2) ¹³	29(1) ¹¹
Cm(III)-HOPO	21.8(4) ¹³	22(5) ¹¹






Fig. 1 Targeting fusion proteins explored in this work incorporate the Siderocalin (Scn) mammalian protein, which recognizes negatively charged M(III)-HOPO complexes (left, non-targeting control), and is fused either to an antibody fragment (Fab, middle) or trastuzumab (IgG, right).

Radio-TLC was used to determine radiochemical yields and construct stability (Table S2, Fig. S6–S9, ESI[†]). Radiochemical yields of 55–90% were obtained for labeled $^{86/90}\text{Y}$ -HOPO-Scn, $^{86/90}\text{Y}$ -HOPO-Fab-Scn, and $^{86/90}\text{Y}$ -HOPO-IgG-Scn. In addition, monitoring of the protein constructs over 72 hours in PBS at room temperature indicated that the isotope stayed bound to the macromolecular fraction.

To evaluate the uptake of the trastuzumab and fragment-functionalized proteins, mice with SKOV-3 xenografts were injected intraperitoneally (I.P., 100 μCi , 0.2 mL) and subsequently imaged at 5, 25, and 50 hours post-injection (p.i.) on a Concorde microPET R4. Our previous *in vivo* imaging of the nontargeted ^{86}Y -HOPO complex demonstrated rapid hepatic

clearance, visualized by uptake primarily in the gastrointestinal tract 15 minutes post-injection with complete clearance after 24 hours.⁹ With a similar amount of activity injected of ^{86}Y , the images collected on the same PET scanner demonstrate comparable signal contrast.⁹ The diminished background signal could be attributed to the 75% emission of gamma-rays from ^{86}Y with energies between 200 and 3000 keV, which have the potential to scatter into the PET imaging window despite the 33% positron branching ratio.^{19,20} Promisingly, for the non-targeting and targeting constructs, no bone or liver uptake was observed in the PET images after 50 hours, indicating the ^{86}Y -HOPO protein constructs do not release yttrium *in vivo* (Fig. 2). Unfortunately, due to non-ideal tumor location on the




Fig. 2 (A) Coronal PET images (mouse lying prone, head at top) of targeting ^{86}Y -HOPO-Scn (left) compared to ^{86}Y -HOPO-IgG-Scn (right). (B) Sagittal view (mouse lying prone, head at top) showing tumor uptake. White dotted circle outlines tumor location. The most uptake is seen in the bladder at 5 h P.I. for both constructs.



back/spine, distinct tumor uptake is difficult to distinguish in the coronal view, but taken together with the sagittal view, uptake was observed with ^{86}Y -HOPO-IgG-Scn (Fig. 2, right). Although most activity is cleared renally through the kidneys and bladder, 2-fold increase in %ID is observed in the tumor after 25 hours and increased to a 3-fold increase in %ID at 50 hours. The gradual increase in uptake along with the renal excretion profile indicates strong *in vivo* stability. The non-targeting control, by contrast, is quickly excreted through the kidneys, with 76% of the injected dose cleared after 25 hours and 98% after 50 hours (Fig. S11, ESI†). However, minimal uptake was observed for the Fab-Scn fusion proteins, likely because the smaller antibody fragment is cleared too quickly before accumulating at the tumor site, a phenomenon observed in other antibody fragment systems²¹ (Fig. S11, ESI†). Further biodistribution studies were carried out by injecting 45 μCi (0.2 mL, I.P.) of ^{90}Y -HOPO-IgG-Scn, ^{90}Y -HOPO-Fab-Scn, and non-targeting ^{90}Y -HOPO-Scn in addition to PBS as a control. Mice were euthanized 24 hours p.i. and organs of interest (liver, kidney, spleen, heart, lung, tumor, and remaining abdominal cavity) were harvested and processed for liquid scintillation counting (Fig. S12, ESI†). Similar to what was observed with the PET images, minimal ^{90}Y deposited in the bone or liver, further confirming no release of free yttrium from the ligand or ligand-protein construct. Instead, the conjugates are each cleared rapidly through the kidneys with minimal residual uptake after 24 hours according to LSC counting and by image analysis at 25 and 50 hours. Efforts are on-going to further establish Scn-IgG uptake *in vitro* and *in vivo* with other ligand and metal systems.

Conclusions

Here we report a rapid, room temperature radiolabeling method *via* $^{86/90}\text{Y}$ -HOPO incorporation into a targeting fusion protein. This opens directions for future fusion protein systems that take advantage of facile radiolabeling and formulation. The rapid non-covalent binding interaction between the negatively charged HOPO complexes and Scn fusion proteins could conceivably allow for purification-free, cold-kit labeling strategies ("mix-and-go"). However, this is the first demonstration of the applicability of fusion siderocalin proteins toward theranostic approaches. Future work aimed at developing a pre-targeting system could improve targeting efficiency and potentially expand to further timepoints to account for longer trastuzumab circulation time.

Author contributions

Conceptualization: AGC, TAB, RKS, RJA; investigation: AGC, TA, TAB, MB, JJW, LMAQ, JAV, JNW, ANG; data curation: AGC, TA, TAB, JAV, RKS, RJA; writing – original draft: AGC; writing – review & editing: AGC, TA, TAB, MB, JJW, LMAQ, JAV, JNW, ANG, RKS, RJA; funding acquisition: RKS, RJA.

Conflicts of interest

RJA and RKS are listed as inventors on patent applications filed by the Lawrence Berkeley National Laboratory (LBNL) and the Fred Hutchinson Cancer Center, describing inventions related to the research results presented here. The authors declare no competing financial interest.

Acknowledgements

All protocols and procedures used in the *in vivo* studies were reviewed and approved by the Institutional Animal Care and Use Committee of LBNL, and were performed in AAALAC accredited facilities, in compliance with guidelines from the Public Health Service's National Institutes of Health Office of Laboratory Animal Welfare. This work was supported by the University of California Contractor Supporting Research Program at LBNL under U.S. Department of Energy (DOE) Contract No. DE-AC02-05CH11231. We acknowledge additional support from the DOE, Office of Science, Office of Basic Energy Sciences, Chemical Sciences, Geosciences, and Biosciences Division at LBNL under Contract DE-AC02-05CH11231, for the spectroscopic characterization of metal-ligand-protein binding. We recognize the National Isotope Development Center managed by the DOE Isotope Program for supplying ^{86}Y .

References

- 1 R. Marcus, Use of ^{90}Y -Ibritumomab Tiuxetan in Non-Hodgkin's Lymphoma, *Semin. Oncol.*, 2005, **32**, 36–43, DOI: [10.1053/j.seminoncol.2005.01.012](https://doi.org/10.1053/j.seminoncol.2005.01.012).
- 2 R. Shannon, Revised Effective Ionic Radii and Systematic Studies of Interatomic Distances in Halides and Chalcogenides, *Acta Crystallogr., Sect. A: Cryst. Phys., Diffr., Theor. Gen. Crystallogr.*, 1976, **32**(5), 751–767, DOI: [10.1107/S0567739476001551](https://doi.org/10.1107/S0567739476001551).
- 3 J. Dewulf, K. Adhikari, C. Vangestel, T. V. Wyngaert and F. Elvas, Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update, *Cancers*, 2020, **12**, 1868.
- 4 E. B. Ehlerding, C. A. Ferreira, E. Aluicio-Sarduy, D. Jiang, H. J. Lee, C. P. Theuer, J. W. Engle and W. Cai, $^{86/90}\text{Y}$ -Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model, *Mol. Pharmaceutics*, 2018, **15**(7), 2606–2613, DOI: [10.1021/acs.molpharmaceut.8b00133](https://doi.org/10.1021/acs.molpharmaceut.8b00133).
- 5 C. A. Ferreira, E. B. Ehlerding, Z. T. Rosenkrans, D. Jiang, T. Sun, E. Aluicio-Sarduy, J. W. Engle, D. Ni and W. Cai, $^{86/90}\text{Y}$ -Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics, *Mol. Pharmaceutics*, 2020, **17**(5), 1697–1705, DOI: [10.1021/acs.molpharmaceut.0c00127](https://doi.org/10.1021/acs.molpharmaceut.0c00127).
- 6 I. Captain, G. J. P. Deblonde, P. B. Rupert, D. D. An, M.-C. Illy, E. Rostan, C. Y. Ralston, R. K. Strong and R. J. Abergel, Engineered Recognition of Tetravalent Zirconium and Thorium by Chelator-Protein Systems: Toward Flexible Radiotherapy and Imaging Platforms, *Inorg. Chem.*,



- 2016, **55**(22), 11930–11936, DOI: [10.1021/acs.inorgchem.6b02041](https://doi.org/10.1021/acs.inorgchem.6b02041).
- 7 L. D. Loomis and K. N. Raymond, Solution Equilibria of Enterobactin and Metal-Enterobactin Complexes, *Inorg. Chem.*, 1991, **30**(5), 906–911, DOI: [10.1021/ic00005a008](https://doi.org/10.1021/ic00005a008).
 - 8 R. J. Abergel, M. C. Clifton, J. C. Pizarro, J. A. Warner, D. K. Shuh, R. K. Strong and K. N. Raymond, The Siderocalin/Enterobactin Interaction: A Link between Mammalian Immunity and Bacterial Iron Transport, *J. Am. Chem. Soc.*, 2008, **130**(34), 11524–11534, DOI: [10.1021/ja803524w](https://doi.org/10.1021/ja803524w).
 - 9 K. P. Carter, G. J. P. Deblonde, T. D. Lohrey, T. A. Bailey, D. D. An, K. M. Shield, W. W. Lukens and R. J. Abergel, Developing Scandium and Yttrium Coordination Chemistry to Advance Theranostic Radiopharmaceuticals, *Commun. Chem.*, 2020, **3**(1), 61, DOI: [10.1038/s42004-020-0307-0](https://doi.org/10.1038/s42004-020-0307-0).
 - 10 M. Sturzbecher-Hoehne, C. Ng Pak Leung, A. D'Aléo, B. Kullgren, A.-L. Prigent, D. K. Shuh, K. N. Raymond and R. J. Abergel, 3,4,3-LI(1,2-HOPO): In Vitro Formation of Highly Stable Lanthanide Complexes Translates into Efficacious in Vivo Europium Decorporation, *Dalton Trans.*, 2011, **40**(33), 8340–8346, DOI: [10.1039/C1DT10840A](https://doi.org/10.1039/C1DT10840A).
 - 11 B. E. Allred, P. B. Rupert, S. S. Gauny, D. D. An, C. Y. Ralston, M. Sturzbecher-Hoehne, R. K. Strong and R. J. Abergel, Siderocalin-Mediated Recognition, Sensitization, and Cellular Uptake of Actinides, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**(33), 10342–10347, DOI: [10.1073/pnas.1508902112](https://doi.org/10.1073/pnas.1508902112) (accessed 2023/01/09).
 - 12 G. J. P. Deblonde, M. Sturzbecher-Hoehne and R. J. Abergel, Solution Thermodynamic Stability of Complexes Formed with the Octadentate Hydroxypyridinonate Ligand 3,4,3-LI(1,2-HOPO): A Critical Feature for Efficient Chelation of Lanthanide(IV) and Actinide(IV) Ions, *Inorg. Chem.*, 2013, **52**(15), 8805–8811, DOI: [10.1021/ic4010246](https://doi.org/10.1021/ic4010246).
 - 13 M. Sturzbecher-Hoehne, B. Kullgren, E. E. Jarvis, D. D. An and R. J. Abergel, Highly Luminescent and Stable Hydroxypyridinonate Complexes: A Step Towards New Curium Decontamination Strategies, *Chem. – Eur. J.*, 2014, **20**(32), 9962–9968, DOI: [10.1002/chem.201402103](https://doi.org/10.1002/chem.201402103) (accessed 2023/01/09).
 - 14 M. A. Deri, S. Ponnala, P. Kozlowski, B. P. Burton-Pye, H. T. Cicek, C. Hu, J. S. Lewis and L. C. Francesconi, p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for ^{89}Zr ImmunoPET, *Bioconjugate Chem.*, 2015, **26**(12), 2579–2591, DOI: [10.1021/acs.bioconjchem.5b00572](https://doi.org/10.1021/acs.bioconjchem.5b00572).
 - 15 P. J. Yazaki, T. Kassa, C.-W. Cheung, D. M. Crow, M. A. Sherman, J. R. Bading, A.-L. J. Anderson, D. Colcher and A. Raubitschek, Biodistribution and Tumor Imaging of an Anti-CEA Single-Chain Antibody–Albumin Fusion Protein, *Nucl. Med. Biol.*, 2008, **35**(2), 151–158, DOI: [10.1016/j.nucmedbio.2007.10.010](https://doi.org/10.1016/j.nucmedbio.2007.10.010).
 - 16 L. Cavina, D. van der Born, P. H. M. Klaren, M. C. Feiters, O. C. Boerman and F. P. J. T. Rutjes, Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination, *Eur. J. Org. Chem.*, 2017, 3387–3414, DOI: [10.1002/ejoc.201601638](https://doi.org/10.1002/ejoc.201601638) (accessed 2023/03/01).
 - 17 A. D. Bandaranayake, C. Correnti, B. Y. Ryu, M. Brault, R. K. Strong and D. J. Rawlings, Daedalus: a Robust, Turnkey Platform for Rapid Production of Decigram Quantities of Active Recombinant Proteins in Human Cell Lines using Novel Lentiviral Vectors, *Nucleic Acids Res.*, 2011, **39**(21), e143, DOI: [10.1093/nar/gkr706](https://doi.org/10.1093/nar/gkr706) (accessed 4/1/2023).
 - 18 C. E. Correnti, M. M. Gewe, C. Mehlin, A. D. Bandaranayake, W. A. Johnsen, P. B. Rupert, M.-Y. Brusniak, M. Clarke, S. E. Burke and W. De Van Der Schueren, *et al.*, Screening, Large-Scale Production and Structure-Based Classification of Cystine-Dense Peptides, *Nat. Struct. Mol. Biol.*, 2018, **25**(3), 270–278, DOI: [10.1038/s41594-018-0033-9](https://doi.org/10.1038/s41594-018-0033-9).
 - 19 F. Rösch, H. Herzog and S. M. Qaim, The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair ^{86}Y and ^{90}Y , *Pharmaceuticals*, 2017, **10**, 56.
 - 20 M. Le Fur and P. Caravan, Chapter Ten— ^{86}Y PET imaging, in *Methods in Enzymology*, ed. J. A. Cotruvo, Academic Press, 2021, vol. 651, pp. 313–342.
 - 21 C. T. Mendler, L. Friedrich, I. Laitinen, M. Schlapschy, M. Schwaiger, H.-J. Wester and A. Skerra, High Contrast Tumor Imaging with Radio-Labeled Antibody Fab Fragments Tailored for Optimized Pharmacokinetics via PASylation, *mAbs*, 2015, **7**(1), 96–109, DOI: [10.4161/19420862.2014.985522](https://doi.org/10.4161/19420862.2014.985522).

